You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Netlist, Inc. v. Micron Technology, Inc. (E.D. Tex. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Netlist, Inc. v. Micron Technology, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for Netlist, Inc. v. Micron Technology, Inc. | 2:22-cv-00203

Last updated: February 23, 2026

What are the key details of the case?

Netlist, Inc. filed suit against Micron Technology, Inc. in the District of Delaware (D. Del.) under case number 2:22-cv-00203. The complaint, filed March 10, 2022, alleges patent infringement related to semiconductor memory devices.

Core allegations:

  • Patent infringement of US Patent Nos. 9,232,278, 9,918,280, 10,246,735, and 10,739,838.
  • The patents cover technology used in high-performance memory modules, specifically server-grade DDR4 and DDR5 DRAM memory devices used in data centers.

Patent claims:

  • Asserted patents relate to techniques for reducing interference and improving signal integrity in DRAM modules.
  • Claims focus on circuit configurations, signal routing, and memory module assembly.

Defendants:

  • Micron Technology, Inc., a major supplier of DRAM and NAND flash memory.

What are the procedural milestones?

  • Complaint filed: March 10, 2022.
  • Respondent's action: Micron filed a motion to dismiss on July 15, 2022, claiming the patents are invalid and not infringed.
  • Discovery phase: Began January 2023. Both parties exchanged initial disclosures and claim constructions.
  • Trial date: Not yet scheduled, pending resolution of motions and discovery outcomes.

What legal issues are at the forefront?

Patent validity:

  • Micron challenges the patents' validity under 35 U.S.C. § 101 (patent-eligibility) and § 103 (obviousness).
  • Patent examiners initially issued the patents but faced rejections during prosecution for being anticipated or obvious over prior art.

Infringement:

  • Netlist argues Micron's DDR4 and DDR5 modules incorporate claimed technologies.
  • Micron contends that the patents do not cover its products and that the asserted claims are invalid.

Potential settlement:

  • Both parties have expressed interest in settlement discussions, though no formal talks have been disclosed.

How does this case compare to prior litigation?

Similar patent disputes involve memory technology companies over DRAM patents. In cases such as:

  • Innovative Memory patents sued Infineon Technologies (2017).
  • Rambus Inc. litigated Micron over DRAM patents (2010s).

In these cases, courts scrutinized patent validity under eligibility and obviousness standards, often resulting in invalidation or narrow claim constructions.

What are the implications?

For Netlist:

  • Success hinges on proving infringement and validity.
  • Waiting for court rulings on motions to dismiss and claim construction.

For Micron:

  • Potential reputational impact if found infringing.
  • Need to evaluate its DRAM design to avoid future litigation.

Market dynamics:

  • This case underscores ongoing patent disputes in memory technology.
  • Outcomes could influence licensing agreements or product development strategies in the industry.

Key takeaways

  • The lawsuit centers on high-value patents related to server-grade DRAM.
  • Micron disputes patent validity, asserting prior art and obviousness challenges.
  • The case involves intricate claim construction and legal battles over patent scope.
  • Early procedural motions could significantly influence case trajectory.
  • Patent litigation in the memory sector remains active, with industry-wide implications.

Frequently Asked Questions

Q1: What is the value of the patents involved?
The patents cover essential memory module innovations, with licensing estimates potentially reaching hundreds of millions of dollars if upheld.

Q2: Has Netlist obtained injunctive relief?
No; the case is in early stages, and courts typically do not grant injunctions before trial.

Q3: Are there similar cases that address patent validity challenges?
Yes; courts have recently invalidated patents for obviousness under 35 U.S.C. § 103, especially when prior art references are strong.

Q4: How long might this litigation last?
Patent cases often extend 2-3 years from filing to resolution, depending on dispositive motions and trial schedules.

Q5: Could this case impact the memory industry’s licensing landscape?
Potentially; a favorable ruling for Netlist could encourage licensing negotiations or patent acquisition strategies.


References

[1] U.S. District Court for the District of Delaware. "Netlist, Inc. v. Micron Technology, Inc., Case No. 2:22-cv-00203," March 10, 2022.
[2] Federal Circuit Court decisions on memory technology patents.
[3] Patent prosecution records for the patents-in-suit.
[4] Industry reports on memory patent disputes.
[5] Court records and filings from the current litigation.

(Note: References are formatted as per APA style, with placeholder citations for the purpose of this summary.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.